Novavax Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Novavax hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$2.84
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Novavax: New Chapter, Questions Remain

Jun 20

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

May 14

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

May 07

Novavax: Another Day Older And Deeper In

Mar 02

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Mar 02

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Mar 01

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Feb 23

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Sep 06

Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook

Mar 05

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von NVAX in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von NVAX gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Novavax Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von NVAX im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (NVAX)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Biotechs)	2.8%
Analystenprognose in 3 Jahren (NVAX)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von NVAX im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von NVAX im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von NVAX, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da NVAX keine Ausschüttungen gemeldet hat.

Novavax Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Novavax: New Chapter, Questions Remain

Novavax, Inc. Submits Application to U.S. FDA for Updated Protein-Based 2024-2025 Formula COVID-19 Vaccine

Novavax, Inc. Notifies Retirement of Filip Dubovsky as President, Research and Development, Effective as of June 30, 2024

Price target increased by 13% to US$21.60

President of Research & Development recently sold US$384k worth of stock

Consensus revenue estimates increase by 13%

President of Research & Development notifies of intention to sell stock

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

New major risk - Financial position

Novavax, Inc. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Novavax, Inc. to Report Q1, 2024 Results on May 10, 2024

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

Novavax, Inc., Annual General Meeting, Jun 13, 2024

Consensus EPS estimates upgraded to US$0.55 loss

New minor risk - Profitability

No longer forecast to breakeven

Consensus EPS estimates upgraded to US$0.80 loss

President of Research & Development exercised options and sold US$14k worth of stock

Consensus estimates of losses per share improve by 28%

Price target decreased by 20% to US$15.40

Novavax: Another Day Older And Deeper In

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Full year 2023 earnings: EPS and revenues miss analyst expectations

Novavax, Inc. Provides Earnings Guidance for First Quarter and Full Year 2024

Consensus EPS estimates upgraded to US$0.39 loss, revenue downgraded

New minor risk - Share price stability

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Novavax, Inc. to Report Q4, 2023 Results on Feb 28, 2024

CEO & Director exercised options and sold US$171k worth of stock

Price target increased by 15% to US$23.25

Novavax, Inc. Announces The Taiwan Food and Drug Administration Grants Emergency Use Authorization for Nuvaxovid™ XBB.1.5 Dispersion for Injection Covid-19 Vaccine (Recombinant, Adjuvanted) (NVX-CoV2601) for Active Immunization to Prevent Covid-19 in Individuals Aged 12 and Older

Novavax, Inc. Announces Changes to Executive Leadership Team

No longer forecast to breakeven

New major risk - Shareholder dilution

Price target increased by 11% to US$24.50

Novavax, Inc. Provides Earnings Guidance for the First Quarter of 2024

Third quarter 2023 earnings released: US$1.26 loss per share (vs US$2.15 loss in 3Q 2022)

No longer forecast to breakeven

Novavax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novavax's Updates Nuvaxovid COVID-19 Vaccine Receives Positive CHMP Opinion in the EU

Forecast to breakeven in 2024

Consensus estimates of losses per share improve by 11%

Forecast to breakeven in 2024

Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Novavax, Inc. Announces Updated Protein-Based XBB Covid Vaccine Induced Neutralizing Responses Against Emerging Subvariants

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 12%

Novavax, Inc. announced that it expects to receive $84.5 million in funding from SK bioscience Co.,Ltd.

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novavax, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Profitability

Consensus estimates of losses per share improve by 24%

New minor risk - Profitability

New major risk - Share price stability

Novavax's Nuvaxovid™? Receives Full Marketing Authorization in the Eu for the Prevention of Covid

Consensus EPS estimates fall by 35%

Novavax, Inc.(NasdaqGS:NVAX) dropped from Russell Midcap Index

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Forecast to breakeven in 2025

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 16% to US$39.33

Consensus EPS estimates upgraded to US$4.96 loss, revenue downgraded

Consensus revenue estimates decrease by 25%

Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook

No longer forecast to breakeven

Price target increased by 23% to US$68.33

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors